Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-03-2018 | Retinal Disorders

Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients

Authors: Cyril Meillon, Pierre Henry Gabrielle, Maxime Luu, Ludwig S. Aho-Glele, Alain M. Bron, Catherine Creuzot-Garcher, for the CFSR research net

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 3/2018

Abstract

Purpose

To assess the rate of hemorrhagic complications after vitreoretinal surgery and the influence of antithrombotic agents.

Methods

Hemorrhagic complications of vitreoretinal procedures performed in seven ophthalmologic centers on patients treated or not treated with antiplatelet (AP) or anticoagulant (AC) agents were prospectively collected. Patients’ characteristics, surgical techniques, and complications were recorded during surgery and for 1 month after.

Results

Eight hundred four procedures were performed between January 2015 and April 2015. Among them, 18.4% were treated with AP agents (n = 148) and 7.8% with AC agents (n = 63), with 18 of them treated with NOACS (new oral anticoagulants). AP or AC agents were continued in 96.5% and 80.7% of cases, respectively. Fifty-three patients (6.6%) developed one or more hemorrhagic complications in one eye during this period. In univariate analysis, AC agents were not associated with hemorrhagic complications (P = 0.329) in contrast to AP (P = 0.005). However, in multivariate analysis, AP agents were no longer associated with hemorrhagic complications and the intraoperative use of endodiathermy was the only factor associated with hemorrhagic complications (P = 0.001).

Conclusions

This study showed that AP and AC agents were not a factor associated with hemorrhagic complications during vitreoretinal surgery. The continuation of these treatments should be considered without risk of severe hemorrhagic complications.

Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE, Anticoagulation F (2008) Delivery of optimized anticoagulant therapy: consensus statement from the anticoagulation forum. Ann Pharmacother 42:979–988CrossRefPubMed

Grzybowski A, Ascaso FJ, Kupidura-Majewski K, Packer M (2015) Continuation of anticoagulant and antiplatelet therapy during phacoemulsification cataract surgery. Curr Opin Ophthalmol 26:28–33CrossRefPubMed

Barequet IS, Sachs D, Shenkman B, Priel A, Wasserzug Y, Budnik I, Moisseiev J, Salomon O (2011) Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy. J Cataract Refract Surg 37:1434–1438CrossRefPubMed

Narendran N, Williamson TH (2003) The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand 81:38–40CrossRefPubMed

Oh J, Smiddy WE, Kim SS (2011) Antiplatelet and anticoagulation therapy in vitreoretinal surgery. Am J Ophthalmol 151:934–939 e933 CrossRefPubMed

Talany G, Guo M, Etminan M (2017) Risk of intraocular hemorrhage with new oral anticoagulants. Eye (Lond) 31:628–631. https://doi.org/10.1038/eye.2016.265 CrossRef

Douketis JD (2002) Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res 108:3–13CrossRefPubMed

Tabandeh H, Sullivan PM, Smahliuk P, Flynn HW Jr, Schiffman J (1999) Suprachoroidal hemorrhage during pars plana vitrectomy. Risk factors and outcomes. Ophthalmology 106:236–242CrossRefPubMed

Kiire CA, Mukherjee R, Ruparelia N, Keeling D, Prendergast B, Norris JH (2014) Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery. Br J Ophthalmol 98:1320–1324CrossRefPubMed

10.

Kong KL, Khan J (2015) Ophthalmic patients on antithrombotic drugs: a review and guide to perioperative management. Br J Ophthalmol 99:1025–1030. https://doi.org/10.1136/bjophthalmol-2014-306036 CrossRefPubMed

11.

Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J (2005) Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62:1217–1220CrossRefPubMed

12.

Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I (2012) Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg 255:811–819CrossRefPubMed

13.

Doyle E, Herbert EN, Bunce C, Williamson TH, Laidlaw DA (2007) How effective is macula-off retinal detachment surgery. Might good outcome be predicted? Eye (Lond) 21:534–540CrossRef

14.

Untereiner O, Seince PF, Chterev V, Leblanc I, Berroeta C, Bourel P, Philip I (2015) Management of direct oral anticoagulants in the perioperative setting. J Cardiothorac Vasc Anesth 29:741–748CrossRefPubMed

15.

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ, American Heart Association Advocacy Coordinating C, Stroke C, Council on Cardiovascular R, Intervention, Council on Clinical C, Council on E, Prevention, Council on A, Thrombosis, Vascular B, Council on C, Critical C, Perioperative, Resuscitation, Council on Cardiovascular N, Council on the Kidney in Cardiovascular D, Council on Cardiovascular S, Anesthesia, Interdisciplinary Council on Quality of C, Outcomes R (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:933–944CrossRefPubMed

16.

Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5:615–621CrossRefPubMedPubMedCentral

17.

Oscarsson A, Gupta A, Fredrikson M, Jarhult J, Nystrom M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C (2010) To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 104:305–312CrossRefPubMed

18.

Burger W, Chemnitius JM, Kneissl GD, Rucker G (2005) Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 257:399–414CrossRefPubMed

19.

Mason JO 3rd, Gupta SR, Compton CJ, Frederick PA, Neimkin MG, Hill ML, Heersink MJ, Vail RS, White MF Jr, Feist RM, Thomley ML, Albert MA Jr (2011) Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group. Ophthalmology 118:543–547CrossRefPubMed

20.

Meyer CH, Callizo J, Mennel S, Kussin A (2007) Perioperative management of anticoagulated patients undergoing repeated intravitreal injections. Arch Ophthalmol 125:994CrossRefPubMed

21.

Childers CP, Maggard-Gibbons M, Shekelle PG (2017) Antiplatelet therapy in patients with coronary stents undergoing elective noncardiac surgery: continue, stop, or something in between? JAMA 318:120–121CrossRefPubMed

22.

Dayani PN, Grand MG (2006) Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Trans Am Ophthalmol Soc 104:149–160PubMedPubMedCentral

23.

Fu AD, McDonald HR, Williams DF, Cantrill HL, Ryan EH Jr, Johnson RN, Ai E, Jumper JM (2007) Anticoagulation with warfarin in vitreoretinal surgery. Retina 27:290–295CrossRefPubMed

24.

Brown JS, Mahmoud TH (2011) Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 31:1983–1987CrossRefPubMed

25.

Patel R, Charles S, Jalil A (2017) Antiplatelets and anticoagulants in vitreoretinal surgery, with a special emphasis on novel anticoagulants: a national survey and review. Graefes Arch Clin Exp Ophthalmol 255:1275–1285CrossRefPubMed

26.

Chan NC, Bhagirath V, Eikelboom JW (2015) Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 11:343–351PubMedPubMedCentral

27.

Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A (2013) European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625–651CrossRefPubMed

28.

Kang TS, Lord K, Kunjukunju N (2014) Spontaneous choroidal hemorrhage in a patient on dabigatran etexilate (Pradaxa). Retin Cases Brief Rep 8:175–177CrossRefPubMed

29.

Grand MG, Walia HS (2016) Hemorrhagic risk of Vitreoretinal surgery in patients maintained on novel oral anticoagulant therapy. Retina 36:299–304CrossRefPubMed

30.

Caldeira D, Canastro M, Barra M, Ferreira A, Costa J, Pinto FJ, Ferreira JJ (2015) Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol 133:834–839CrossRefPubMed

31.

Passemard M, Koehrer P, Juniot A, Bron AM, Creuzot-Garcher C (2012) Maintenance of anticoagulant and antiplatelet agents for patients undergoing peribulbar anesthesia and vitreoretinal surgery. Retina 32:1868–1873CrossRefPubMed

32.

Chandra A, Jazayeri F, Williamson TH (2011) Warfarin in vitreoretinal surgery: a case controlled series. Br J Ophthalmol 95:976–978CrossRefPubMed

33.

Chandra A, Xing W, Kadhim MR, Williamson TH (2014) Suprachoroidal hemorrhage in pars plana vitrectomy: risk factors and outcomes over 10 years. Ophthalmology 121:311–317CrossRefPubMed

34.

Smith JM, Steel DH (2015) Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev: CD008214

35.

Sousa DC, Leal I, Costa J, Vaz-Carneiro A (2017) Analysis of the Cochrane review: anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity hemorrhage after Vitrectomy for proliferative diabetic retinopathy. Cochrane database Syst rev. 2015;8:CD008214. Acta Medica Port 30:513–516CrossRef

Title: Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients
Authors: Cyril Meillon
Pierre Henry Gabrielle
Maxime Luu
Ludwig S. Aho-Glele
Alain M. Bron
Catherine Creuzot-Garcher
for the CFSR research net
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 3/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3897-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Safety study of intravitreal and suprachoroidal Laponite clay in rabbit eyes

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

Functional and anatomical outcomes following surgical management of persistent fetal vasculature: a single-center experience of 44 cases

MIGS: therapeutic success of combined Xen Gel Stent implantation with cataract surgery

Generation and characterisation of decellularised human corneal limbus

Bilateral lateral rectus recession versus unilateral recession resection for basic intermittent exotropia: a meta-analysis